Wantstats
Company ProfilePremium

SIGA Technologies

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
SIGA Technologies - Healthcare showcase

Year Founded & Workforce

1995

50 Employees

Industry

Healthcare
S

SIGA Technologies Employee Contacts

5 verified contactsNames, job titles, seniority and locations

View Employee Contacts

SIGA Technologies Overview

Company Headquarters: New York, US

Founded: 1995

Workforce: ~50

Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government

Strategy

SIGA's business strategy includes ongoing international sales of TPOXX to foreign governments. Foreign governments, as well as state and local governments, non-governmental organizations focused on global health such as the World Health Organization, health care institutions such as hospitals (domestic and foreign), and certain large business organizations interested in protecting their employees from global threats and first responders in the event of an emergency are among the non-US Government customers

Company Snapshot

$115.5M

Revenue

50

Employees

1995

Founded

New York, US

Headquarters

SWOT Analysis

Strengths

  • High focus on innovation
  • Continually invests in research and development
  • Increasingly flexible and adaptive to change

Weaknesses

  • Restricted patent protection
  • Stagnant groups of target consumers
  • No expansion in emerging economies

Opportunities

  • Development of strategic alliances and partnerships
  • Focus on building a high service culture

Threats

  • High competition
  • Government regulations and policies
  • High price volatility and fluctuations in the acquisition of raw materials

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
September 2022InvestmentSIGA Technologies announced new contract awarded by U.S. Department of Defense for the procurement of up to 10.7 million of oral TPOXX.
July 2022Product ApprovalSIGA Technologies announced that the UK has approved SIGA's oral tecovirimat (also known as oral TPOXX in the United States) for the treatment of smallpox, monkeypox, cowpox, and vaccinia problems following smallpox immunization in adults and children weighing at least 13kg.
May 2022Product ApprovalSIGA Technologies announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox. The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX.
July 2021CollaborationSIGA Technologies established a collaboration with Oxford University in the United Kingdom (UK) to supply TPOXX (tecovirimat) under an expanded access policy to treat monkeypox patients in the Central African Republic (CAR). The protocol and study in CAR will be sponsored by Oxford University, and SIGA will supply up to 500 free courses of TPOXX (tecovirimat).
June 2019AgreementSIGA Technologies has announced an international promotion agreement with Meridian Medical Technologies, Inc. (US) ("Meridian", a Pfizer Company). Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all markets excluding the United States and South Korea under the terms of the agreement. SIGA will retain ownership of all rights in the US market.

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 115.5 Mn in 2020 to USD 86.7 Mn in 2022.
SIGA Technologies — By Business Segment
Series (USD Mn)202020212022
Sales115.5126.886.7
R&D9.56.924.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →